- Home
- BRT vs ATYR Comparison
BRT vs ATYR Comparison
Compare BRT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | ATYR |
|---|---|---|
| Founded | 1972 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.2M | 49.2M |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BRT | ATYR |
|---|---|---|
| Price | $13.89 | $0.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $19.75 | $3.67 |
| AVG Volume (30 Days) | 35.7K | ★ 728.9K |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | ★ 6.98 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $97,028,000.00 | $190,000.00 |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $5.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $13.18 | $0.37 |
| 52 Week High | $16.50 | $1.12 |
Technical Indicators
Market Signals| Indicator | BRT | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 25.85 |
| Support Level | $13.18 | N/A |
| Resistance Level | $14.87 | $0.59 |
| Average True Range (ATR) | 0.29 | 0.03 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 16.67 | 2.13 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).